Document is current
Any future updates will be listed below
-
Authors
Margraf, Andreas https://orcid.org/0000-0002-6539-6478
Chen, Jianmin
Christoforou, Marilena
Claria-Ribas, Pol
Henriques Schneider, Ayda
Cecconello, Chiara https://orcid.org/0009-0002-8469-4072
Bu, Weifeng
Imbert, Paul R C https://orcid.org/0000-0002-1870-1249
Wright, Thomas D https://orcid.org/0009-0006-4898-3298
Russo, Stefan https://orcid.org/0000-0002-2234-5515
Blacksell, Isobel A
Koenis, Duco S
Dalli, Jesmond
Lupisella, John A https://orcid.org/0000-0003-1343-6412
Wurtz, Nicholas R
Garcia, Ricardo A
Cooper, Dianne
Norling, Lucy V https://orcid.org/0000-0001-5316-9115
Perretti, Mauro https://orcid.org/0000-0003-2068-3331
-
Funding
Funding for this research was provided by:
Versus Arthritis UK (22235)
Versus Arthritis UK (22855)
Chernajovsky Foundation (N/A)
Deutsche Forschungsgemeinschaft (460682455)
Deutsche Forschungsgemeinschaft (431460824)
British Heart Foundation (IG/17/2/32993)
Bristol Myers Squibb Foundation (N/A)
Barts Charity (U0026)
- License Information
-
More Information
Article History
Received: 1 August 2024
Revised: 12 March 2025
Accepted: 17 March 2025
First Online: 3 April 2025
Disclosure and competing interests statement
: MP declares to be a shareholder of ResoTher Pharma ApS and a director of William Harvey Research Limited; advisory board member for SynAct Pharma AB; and is involved in the following commercial projects: SynAct Pharma AB and TXP Pharma AG. MP and JD are inventors on a patent related to AnxA1 pro-resolving peptides (European Patent 3533457 B1). JAL, NRW and RAG are employees of Bristol Myers Squibb and hold shares in the company.
